( NASDAQ-NMS:MYL )

News from mylan inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 12, 2015, 12:30 ET Mylan N.V. and Mylan Inc. Announce Successful Completion of Consent Solicitations for Mylan Inc.'s Notes

Mylan N.V. (NASDAQ: MYL) (the "Parent") and Mylan Inc. ("Mylan" and, together with the Parent, the "Companies") today announced the successful...


Mar 11, 2015, 07:30 ET Mylan Launches Generic Subutex® Sublingual Tablets

 Mylan N.V. (NASDAQ: MYL) and Mylan Inc. today announced the U.S. launch of Buprenorphine Hydrochloride Sublingual Tablets, 2 mg and 8 mg,...


Mar 03, 2015, 08:55 ET Mylan N.V. and Mylan Inc. Announce Commencement of Consent Solicitations for Mylan Inc.'s Notes

Mylan N.V. (NASDAQ: MYL) (the "Parent") and Mylan Inc. ("Mylan" and, together with the Parent, the "Companies") today...


Mar 02, 2015, 16:11 ET Mylan Fourth Quarter 2014 Adjusted Diluted EPS Increases 35% to $1.05 and Full Year Adjusted Diluted EPS Up 23% to $3.56

 Mylan N.V. (Nasdaq: MYL) and Mylan Inc. today announced Mylan Inc.'s financial results for the quarter and year ended December 31,...


Feb 27, 2015, 12:30 ET Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business

Mylan N.V. and Mylan Inc. (Nasdaq: MYL) today announced the successful completion of the acquisition of Abbott Laboratories' (NYSE: ABT) non-U.S....


Feb 23, 2015, 10:45 ET Mylan Specialty to Present Findings from EpiPen4Schools® Program Survey

 Mylan Specialty, the full integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL),...


Feb 23, 2015, 07:00 ET Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India

 Mylan Inc. (Nasdaq: MYL) today announced that its Indian subsidiary, Mylan Pharmaceuticals Private Limited, has entered into an agreement with...


Feb 09, 2015, 11:45 ET Mylan Schedules Fourth Quarter and Year End 2014 Financial Results Conference Call and Live Webcast

Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast, including a slide presentation, on Monday, March 2,...


Feb 09, 2015, 11:00 ET Mylan Confirms First-to-File Patent Challenge Relating to NEXAVAR®

 Mylan Inc. (Nasdaq: MYL) today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by Bayer Healthcare LLC, Bayer...


Feb 02, 2015, 07:00 ET Theravance Biopharma, Inc. and Mylan Partner to Develop and Commercialize a Novel LAMA Compound, TD-4208, for COPD

 Theravance Biopharma, Inc. (NASDAQ: TBPH) and Mylan Inc. (NASDAQ: MYL) today announced that the two companies will partner on the development...


Feb 02, 2015, 06:44 ET Mylan to Acquire Famy Care Businesses to Create a Leading Women's Health Care Franchise

 Mylan Inc. (Nasdaq: MYL) today announced that it has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement...


Nov 07, 2014, 08:00 ET Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors

Mylan Inc. (Nasdaq: MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help...


Aug 28, 2014, 11:21 ET Mylan's ANDA for Three Times Per Week Generic Copaxone® 40 mg/mL Accepted for Filing by FDA

 Mylan Inc. (Nasdaq: MYL) today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate...


Aug 22, 2014, 07:30 ET Mylan Launches First Generic Klor-Con® Extended-Release Tablets

 Mylan Inc. (Nasdaq: MYL) today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750...


Aug 19, 2014, 11:42 ET Mylan Launches Generic Precedex™ Injection - Another Key Product Approval

 Mylan Inc. (Nasdaq: MYL) announced that its business Mylan Institutional has launched Dexmedetomidine Hydrochloride Injection, 100 mcg...


Aug 11, 2014, 07:30 ET Mylan Launches Generic Xeloda® Tablets

Mylan Inc. (Nasdaq: MYL) today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's...


Aug 07, 2014, 06:30 ET Mylan Reports Second Quarter 2014 Adjusted Diluted EPS of $0.69, In Line With Guidance

Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and six months ended June 30, 2014. Second Quarter 2014...


May 01, 2014, 07:00 ET Mylan First Quarter 2014 Adjusted Diluted EPS Increases 6% to $0.66

 Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months ended March 31, 2014. Financial Highlights -...


Apr 25, 2014, 18:21 ET Mylan Challenges FDA Ruling on Exclusivity Relating to Celecoxib

 Mylan Inc. (Nasdaq: MYL) today announced that it has filed suit against the U.S. Food and Drug Administration (FDA), challenging the agency's...


Apr 18, 2014, 20:45 ET Supreme Court Chief Justice Denies Teva's Request for an Injunction Relating to Generic Copaxone®; Clears Legal Hurdle for Mylan to Launch at Market Formation

 Mylan Inc. (Nasdaq: MYL) today announced that Supreme Court Chief Justice Roberts has denied Teva's application for an injunction seeking to...


Apr 16, 2014, 16:13 ET Mylan Launches First Generic ORTHO EVRA® Patch

Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE™ (Norelgestromin /...


Apr 15, 2014, 10:20 ET Mylan Announces Settlement Agreement for First-to-File Generess® Fe

Mylan Inc. (Nasdaq: MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner...


Apr 15, 2014, 10:08 ET Mylan Launches Generic Lunesta® Tablets

 Mylan Inc. (Nasdaq: MYL) today announced that it has launched Eszopiclone Tablets 1 mg, 2 mg and 3 mg, the generic version of Sunovion...


Apr 15, 2014, 08:00 ET Actavis Announces Agreement Related to Generess® FE Patent Challenge Litigation

Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent...


Apr 15, 2014, 08:00 ET Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory Products Flixotide® and Flovent®

 Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced...